Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Imdusiran (AB-729)
Imdusiran · 1 trial · 1 indication
Intrahepatic drug concentration at day 0 (peak) and week 32 (trough)
| Arm | Type | Description |
|---|---|---|
| Imdusiran (AB-729) | EXPERIMENTAL | Participants receive subcutaneous injections of 60mg, one injection every 8 weeks for 4 doses. |
| Name | Type | Description |
|---|---|---|
| Imdusiran (AB-729) | DRUG | 60mg subcutaneously, every 8 weeks, for a total of 4 doses |
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, over 18 years of age on the date of screening 4. In good general health as evidenced by medical hist...
Imdusiran is an investigational small molecule being developed for the treatment of chronic Hepatitis B. It is currently in Phase 2 clinical development and has received Fast Track designation from the FDA. The drug is being studied in patients with chronic Hepatitis B.
Imdusiran is a small interfering RNA (siRNA) agent. It is designed to target and silence specific genes involved in the Hepatitis B virus life cycle. By using RNA interference, Imdusiran aims to reduce viral protein production and potentially achieve a functional cure for chronic Hepatitis B.
Imdusiran is being developed by Arbutus Biopharma Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ABUS. The company is focused on developing therapies for Hepatitis B and other infectious diseases.
Imdusiran is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by the FDA. The drug has received Fast Track designation, which is intended to expedite the development and review of therapies for serious conditions.
Imdusiran is being evaluated in a Phase 2 clinical trial with the identifier NCT06154278. This study is titled 'Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B' and is currently recruiting participants in the United States. The trial is an uncontrolled, open-label study enrolling approximately 10 adult patients.
Yes, Imdusiran is also known as AB-729. The drug is referred to by both names in clinical research and development contexts. The ongoing Phase 2 trial NCT06154278 uses both names in its official title, confirming that Imdusiran and AB-729 refer to the same investigational agent.